Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma
Public ClinicalTrials.gov record NCT00002524. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Pilot Study in AIDS-Related Lymphomas
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with AIDS-related lymphoma.
Study identification
- NCT ID
- NCT00002524
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 46 participants
Conditions and interventions
Conditions
Interventions
- Bleomycin Sulfate Biological
- Filgrastim Biological
- Cisplatin Drug
- Cyclophosphamide Drug
- Cytarabine Drug
- Doxorubicin Hydrochloride (DOX) Drug
- Etoposide Drug
- Fluorouracil Drug
- Ifosfamide Drug
- Leucovorin calcium Drug
- Methotrexate Drug
- Methylprednisolone Drug
- Pentamidine Drug
- Prednisone Drug
- Trimethoprim-Sulfamethoxazole Drug
- Vincristine Sulfate Drug
- Zidovudine (AZT) Drug
- Radiation Therapy Radiation
Biological · Drug · Radiation
Eligibility (public fields only)
- Age range
- 15 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 1993
- Primary completion
- Sep 30, 2005
- Completion
- Sep 30, 2005
- Last update posted
- Jul 29, 2012
1993 – 2005
United States locations
- U.S. sites
- 2
- U.S. states
- 2
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| MD Anderson Cancer Center Orlando | Orlando | Florida | 32806 | — |
| University of Texas - MD Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00002524, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 29, 2012 · Synced Sep 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00002524 live on ClinicalTrials.gov.